Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct 15;7(10):356.
doi: 10.3390/jcm7100356.

Drug-Induced Interstitial Lung Disease: A Systematic Review

Sarah Skeoch  1   2 , Nicholas Weatherley  3 , Andrew J Swift  4 , Alexander Oldroyd  5 , Christopher Johns  6 , Conal Hayton  7 , Alessandro Giollo  8   9 , James M Wild  10 , John C Waterton  11   12 , Maya Buch  13 , Kim Linton  14 , Ian N Bruce  15   16 , Colm Leonard  17 , Stephen Bianchi  18 , Nazia Chaudhuri  19
Affiliations
Review

Drug-Induced Interstitial Lung Disease: A Systematic Review

Sarah Skeoch et al. J Clin Med. .

Abstract

Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous agents, but the risk often only becomes apparent after the marketing authorisation of such agents.

Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the current literature on DIILD.

Results: Following a quality assessment, 156 full-text papers describing more than 6000 DIILD cases were included in the review. However, the majority of the papers were of low or very low quality in relation to the review question (78%). Thus, it was not possible to perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3⁻5% of prevalent ILD cases. Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents, and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50% were reported in some studies. Severity at presentation was the most reliable predictor of mortality. Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined their effect on outcome.

Conclusions: Overall high-quality evidence in DIILD is lacking, and the current review will inform larger prospective studies to investigate the diagnosis and management of DIILD.

Keywords: drug-induced interstitial lung disease; drug-induced pneumonitis; pulmonary toxicity.

PubMed Disclaimer

Conflict of interest statement

J.C.W. reports grants from the Innovative Medicines Initiatives 2 Joint Undertaking under grant agreement No. 116106 (this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA), during the conduct of the study; personal fees from Bioxydyn Ltd., outside the submitted work; N.C. reports grants from Boehringer Ingelheim, personal fees from Roche, personal fees from Intermune, outside the submitted work; I.N.B. reports grants and other from GSK, grants from UCB Pharma, other from Merck Serono, other from Astra Zeneca, other from Eli Lilly, grants from Genzyme Sanofi, outside the submitted work.

Figures

Figure 1
Figure 1
Search terms used in Medline, Embase and Cochrane Register of Controlled Trials.
Figure 2
Figure 2
Flow diagram of the review process from abstract review to final inclusion. In total, these 156 articles report approximately 6200 patients with confirmed or suspected DIILD, which was fatal in around 672/2647 (25.4%) cases.
Figure 3
Figure 3
Summary of quality and bias, as assessed using the Grading Recommendations Assessment and Development Evidence (GRADE) method [4]. (A) Summarises risk of bias and (B) summarises quality of included studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Imaging side effects and complications of chemotherapy and radiation therapy: a pictorial review from head to toe.
    Albano D, Benenati M, Bruno A, Bruno F, Calandri M, Caruso D, Cozzi D, De Robertis R, Gentili F, Grazzini I, Micci G, Palmisano A, Pessina C, Scalise P, Vernuccio F, Barile A, Miele V, Grassi R, Messina C; Young SIRM Working Group. Albano D, et al. Insights Imaging. 2021 Jun 10;12(1):76. doi: 10.1186/s13244-021-01017-2. Insights Imaging. 2021. PMID: 34114094 Free PMC article. Review.
  • Sertraline as a rare cause of interstitial lung disease.
    Lepore M, Campbell N. Lepore M, et al. Oxf Med Case Reports. 2021 Apr 28;2021(4):omab014. doi: 10.1093/omcr/omab014. eCollection 2021 Apr. Oxf Med Case Reports. 2021. PMID: 33948187 Free PMC article.
  • Progressive Pulmonary Fibrosis: Where Are We Now?
    Kang HK, Song JW. Kang HK, et al. Tuberc Respir Dis (Seoul). 2024 Apr;87(2):123-133. doi: 10.4046/trd.2023.0119. Epub 2023 Dec 18. Tuberc Respir Dis (Seoul). 2024. PMID: 38111100 Free PMC article.
  • A case of interstitial lung disease following Oxford-AstraZeneca COVID-19 vaccination.
    Taverner JVB, Robertson JG. Taverner JVB, et al. Intern Med J. 2022 Jul;52(7):1276-1277. doi: 10.1111/imj.15850. Intern Med J. 2022. PMID: 35879232 Free PMC article. No abstract available.
  • Emerging technologies and their impact on regulatory science.
    Anklam E, Bahl MI, Ball R, Beger RD, Cohen J, Fitzpatrick S, Girard P, Halamoda-Kenzaoui B, Hinton D, Hirose A, Hoeveler A, Honma M, Hugas M, Ishida S, Kass GE, Kojima H, Krefting I, Liachenko S, Liu Y, Masters S, Marx U, McCarthy T, Mercer T, Patri A, Pelaez C, Pirmohamed M, Platz S, Ribeiro AJ, Rodricks JV, Rusyn I, Salek RM, Schoonjans R, Silva P, Svendsen CN, Sumner S, Sung K, Tagle D, Tong L, Tong W, Eijnden-van-Raaij JVD, Vary N, Wang T, Waterton J, Wang M, Wen H, Wishart D, Yuan Y, Slikker W Jr. Anklam E, et al. Exp Biol Med (Maywood). 2022 Jan;247(1):1-75. doi: 10.1177/15353702211052280. Epub 2021 Nov 16. Exp Biol Med (Maywood). 2022. PMID: 34783606 Free PMC article. Review.
See all "Cited by" articles

References

    1. Travis W.D., Costabel U., Hansell D.M., King T.E., Jr., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M.I., Wells A.U., et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
    1. Cancer Therapy Evaluation Program DoCTaDNCINIoH. Common Terminology Criteria for Adverse Events [Internet]. Version 5.0. 27-11-2017. [(accessed on 13 October 2018)]; Available online: http://ctep.cancer.gov.
    1. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. J. Clin. Epidemiol. 2009;62:1006–1012. doi: 10.1016/j.jclinepi.2009.06.005. - DOI - PubMed
    1. Guyatt G.H., Oxman A.D., Schunemann H.J., Tugwell P., Knottnerus A. GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J. Clin. Epidemiol. 2011;64:380–382. doi: 10.1016/j.jclinepi.2010.09.011. - DOI - PubMed
    1. Koo L.C., Clark J.A., Quesenberry C.P., Higenbottam T., Nyberg F., Wolf M.K., Steinberg M.H., Forsythe B.H. National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: An analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol. Drug Saf. 2005;14:775–787. doi: 10.1002/pds.1071. - DOI - PubMed